• LC–MS/MS Tracks GS-441524 Prodrug Conversion

  2026-09-28

  A January 2026 Microchemical Journal study used LC–MS/MS to follow NGP-1, a novel GS-441524 prodrug, and GS-441524 across simulated gastric conditions, rat blood, liver microsomes, and a rat liver-injury model. Its findings suggest that conversion can occur before and after absorption, highlighting why pharmacokinetic studies should measure prodrug and nucleoside separately while recognizing that this work does not establish human exposure or intracellular antiviral activation.

• HyperScribe T7 High Yield Cy3 RNA Labeling Kit

  2026-09-27

  Generate fluorescent RNA probes for in situ hybridization and Northern blotting with a T7 transcription workflow that lets you tune Cy3 incorporation against RNA yield. Practical setup guidance connects probe quality to biological questions while keeping fluorescent labeling distinct from therapeutic mRNA delivery.

• Ivermectin: Better Assays, Stronger Mechanistic Claims

  2026-09-26

  Ivermectin is a broad-spectrum anti-parasitic, but reliable research depends on separating compound handling, target engagement, and biological outcomes. This article applies that assay logic to parasitology and uses a pancreatic cancer study to illustrate why phenotype alone cannot establish mechanism.

• RNA Pol II Loss Triggers Transcription-Independent Apoptosis

  2026-09-25

  Harper et al. show that loss of RNA polymerase II can trigger apoptosis through a signaling response to depletion of hypophosphorylated Rpb1, rather than through transcriptional shutdown alone. Their genetic and drug-profiling results define the Pol II degradation-dependent apoptotic response (PDAR) and provide a framework for distinguishing loss of a protein from loss of its enzymatic activity.

• Estradiol–Autophagy Signaling in Perimenopausal Aging

  2026-09-25

  Combining NHANES data, network pharmacology, and perimenopausal mouse experiments, this study links lower estradiol with cardiometabolic and kidney risks and tests a receptor-dependent autophagy mechanism for multi-organ protection. Its findings support further investigation of estrogen receptor signaling in fibrosis, while leaving questions about causality, receptor-specific effects, and translation to human therapy open.

• Doxorubicin Beyond Tumor Killing: A Translational Lens

  2026-09-24

  Doxorubicin is a powerful cancer research benchmark, but its translational value depends on studying tumor response alongside normal-tissue injury. Evidence from cardiomyocyte, tumor-cell, mouse, and human iPSC-derived cardiomyocyte models suggests a path for testing cardioprotection without assuming that tumor efficacy is preserved.

• Beyond Cytokines: TPCA-1 in Inflammation Research

  2026-09-24

  TPCA-1 offers a selective way to probe IKK-2 and NF-κB-dependent inflammatory signaling. Here, we connect its established cytokine and arthritis-model evidence with RIPK1 regulation, while outlining practical strategies and the limits of that mechanistic bridge.

• Angiotensin Peptides Boost Spike–Receptor Binding

  2026-09-23

  Oliveira and colleagues report that several naturally occurring angiotensin peptides increase antibody-detected binding between SARS-CoV-2 spike protein and host receptors, with the strongest reported effect for angiotensin IV. The results identify peptide sequence and modification as variables for receptor-binding assays, but do not establish that these effects increase viral infection or alter COVID-19 outcomes.

• Intravesical p21 mRNA-LNP Therapy in Bladder Cancer

  2026-09-23

  The reference study develops chemically modified CDKN1A/p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its cell and orthotopic mouse data support tumor-suppressor replacement as a nonviral approach that restores nuclear p21, restrains cell-cycle signaling, and limits systemic exposure.

• DiscoveryProbe FDA-Approved Drug Library: Mechanistic HTS

  2026-09-22

  Explore how the DiscoveryProbe FDA-approved Drug Library converts broad pharmacology into mechanism-aware screening decisions. This guide connects the collection to assay design, ICOS/ICOSL research, drug repositioning screening, and translational validation.

• Radiation-Altered Neuronal Differentiation via mGluR1

  2026-09-22

  Eom et al. showed that ionizing radiation does more than reduce neural stem-cell viability: it promotes an altered neuronal differentiation program in C17.2 cells through PI3K-STAT3-mGluR1 and PI3K-p53 signaling. The study combines morphology, neuronal marker analysis, receptor-gene profiling, pathway inhibition, and primary neural stem-cell validation to connect radiation exposure with potentially dysfunctional neuronal maturation.

• LGK-974: A Mechanistic Wnt Assay Tool

  2026-09-21

  LGK-974 is a potent PORCN inhibitor for dissecting ligand-dependent Wnt signaling in cancer models. This article connects its assay utility with recent pancreatic cancer findings and shows how to distinguish extracellular Wnt dependence from downstream pathway activation.

• Shufeng Xingbi Therapy in Allergic Rhinitis Rats

  2026-09-21

  This bioRxiv preprint examines how Shufeng Xingbi Therapy affects allergic rhinitis in rats through coordinated changes in nasal inflammation, Th1/Th2-associated signaling, intestinal microbiota, and short-chain fatty acids. Its integrated gut–nose experimental framework is informative for mechanism generation, although the findings remain preclinical and do not establish microbiota-mediated causality.

• DiscoveryProbe FDA-approved Drug Library for HDT

  2026-09-20

  Explore how the DiscoveryProbe FDA-approved Drug Library supports host-directed therapy, drug repositioning screening, and mechanism-aware phenotypic assays. This guide translates evidence from loperamide research into practical decisions for infection, cancer, and neurobiology workflows.

• SAG Workflows for Hedgehog Signaling Research

  2026-09-19

  Build cleaner Hedgehog pathway activation assays with SAG, a downstream Smoothened receptor agonist that separates receptor signaling from ligand presentation. This guide connects cell-based pathway rescue, mitochondrial studies, developmental models, and troubleshooting to practical experimental decisions.

8065 records 1/538 page Next 12345 下5页 Last page